Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival by Ino, K et al.
Angiotensin II type 1 receptor expression in ovarian cancer and its
correlation with tumour angiogenesis and patient survival
K Ino
1, K Shibata
1, H Kajiyama
1, E Yamamoto
1, T Nagasaka
2, A Nawa
1, S Nomura
1 and F Kikkawa
1
1Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan;
2Division of Pathology/Clinical Laboratory, Nagoya University Graduate School of Medicine, Nagoya, Japan
Angiotensin II, a main effector peptide in the renin–angiotensin system, acts as a growth-promoting and angiogenic factor via type 1
angiotensin II receptors (AT1R). We have recently demonstrated that angiotensin II enhanced tumour cell invasion and vascular
endothelial growth factor (VEGF) secretion via AT1R in ovarian cancer cell lines in vitro. The aim of the present study was to
determine whether AT1R expression in ovarian cancer is correlated with clinicopathological parameters, angiogenic factors and
patient survival. Immunohistochemical staining for AT1R, VEGF, CD34 and proliferating cell nuclear antigen (PCNA) were analysed in
ovarian cancer tissues (n¼67). Intratumour microvessel density (MVD) was analysed by counting the CD34-positive endothelial cells.
Type 1 angiotensin II receptors were expressed in 85% of the cases examined, of which 55% were strongly positive. Type 1
angiotensin II receptors expression was positively correlated with VEGF expression intensity and MVD, but not with histological
subtype, grade, FIGO stage or PCNA labelling index. In patients who had positive staining for AT1R, the overall survival and
progression-free survival were significantly poor (P¼0.041 and 0.017, respectively) as compared to those in patients who had
negative staining for AT1R, although VEGF, but not AT1R, was an independent prognostic factor on multivariate analysis. These results
demonstrated that AT1R correlated with tumour angiogenesis and poor patient outcome in ovarian cancer, suggesting its clinical
potential for a novel molecular target in strategies for ovarian cancer treatment.
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Ovarian cancer is the leading cause of death from female genital
malignancies despite significant advances in diagnosis and
treatment (McGuire and Markman, 2003). Several clinicopatho-
logical parameters have been reported to be of prognostic
significance in ovarian cancer, including disease stage, histological
grade, histological subtype, residual tumour volume, presence of
cytologically malignant ascites and response to chemotherapy
(Omura et al, 1991; Chi et al, 2001). In addition to these
established clinical parameters, the identification of biochemical
or molecular markers more strictly related to intrinsic tumour cell
behaviour in ovarian cancer and its characteristic progression
pathway may be helpful in improving the survival of patients with
this disease.
Angiotensin II, a multifunctional bioactive peptide in the renin–
angiotensin system (RAS), plays a fundamental role in controlling
cardiovascular and renal homeostasis. Angiotensin II also acts as a
potent growth factor not only for vascular smooth muscle cells, but
also for certain cancer cell lines (Fujimoto et al, 2001; Muscella
et al, 2002). In addition, angiotensin II stimulates angiogenesis
via the upregulation of vascular endothelial growth factor (VEGF)
(Le Noble et al, 1993; Chua et al, 1998; Pupilli et al, 1999; Tamarat
et al, 2002). These cellular effects of angiotensin II are mostly
mediated through specific G-protein-coupled AT1R.
Recent studies have proposed the concept of a localized tissue
RAS in various organs (Nielsen et al, 1995), and activation of the
RAS has been demonstrated under neoplastic conditions (Inwang
et al, 1997; Takeda and Kondo, 2001; Juillerat-Jeanneret et al,
2004). In the tumour-related RAS, angiotensin II is abundantly
generated from angiotensin I by angiotensin-converting enzyme
(ACE), and AT1R expression is generally upregulated. Previous
studies showed that the angiotensin II–AT1R system is deeply
involved in tumour growth, metastasis and angiogenesis in
experimental animal models, suggesting a therapeutic potential
of RAS blockade using an ACE inhibitor or AT1R blocker (Rivera
et al, 2001; Yoshiji et al, 2001; Fujita et al, 2002; Miyajima et al,
2002; Egami et al, 2003; Uemura et al, 2003; Arrieta et al, 2005).
In gynaecological malignancies, prior studies at our laboratory
demonstrated that angiotensin II stimulated in vitro cell prolifera-
tion, invasion, or VEGF secretion via AT1R in cervical cancer
(Kikkawa et al, 2004; Suganuma et al, 2004), endometrial cancer
(Watanabe et al, 2003) and choriocarcinoma (Ino et al, 2003).
Recently, we were the first to show that AT1R is expressed in
human ovarian cancer cells and angiotensin II enhanced tumour
cell invasion and VEGF expression/secretion via AT1R (Suganuma
et al, 2005). Furthermore, we demonstrated that AT1R blocker
suppresses angiogenesis and the peritoneal dissemination of
ovarian cancer in a mouse model (Suganuma et al, 2005). These
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sresults prompted us to hypothesize that angiotensin II acts as an
angiogenic and tumour-progressive factor for ovarian cancer, and
that AT1R may have clinical potential as a novel molecular target
or as a prognostic indicator in the treatment of ovarian cancer, as
well as in other gynaecological malignancies.
Based on these findings, the present study examined the
immunohistochemical expression of AT1R in ovarian cancer
tissues to determine whether AT1R expression is correlated with
clinicopathological factors or angiogenic parameters, including
VEGF expression and intratumour microvessel density (MVD).
Furthermore, we assessed whether AT1R correlates with the
prognosis of ovarian cancer patients.
MATERIALS AND METHODS
Reagents and antibodies
Rabbit polyclonal antibody against AT1R (306) was purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit
anti-human VEGF polyclonal antibody (A-20) was also purchased
from Santa Cruz. Mouse monoclonal antibody against human
CD34, a marker of endothelial cells, was obtained from Immuno-
tech (Marseille, France). Antiproliferating cell nuclear antigen
(PCNA) monoclonal antibody PC10 was purchased from Dako
(Glostrup, Denmark).
Patients and tissue samples
Human epithelial ovarian cancer tissues (n¼67) were obtained
from patients who underwent surgical treatment at Nagoya
University Hospital between 1993 and 2002. Surgical treatment
consisted of total abdominal hysterectomy and bilateral salpingo-
oophorectomy, followed by surgical staging and/or debulking
surgery (if necessary). All tissue samples were fixed in 10%
formalin, embedded in paraffin, and routinely stained with
haematoxylin and eosin for histological examination. The histo-
logical cell types and histological grade (tumour differentiation)
were assigned according to the criteria of the World Health
Organization (WHO) classification. Clinical staging was reviewed
based on the International Federation of Gynecology and
Obstetrics (FIGO) staging system. The patients received post-
operative chemotherapy with platinum plus cyclophosphamide
and doxorubicin (before 1997), or platinum plus paclitaxel (after
1997) for high-risk early stage (stage I with grade 3; stage IC; any
stage II) or advanced diseases (stages III and IV). Tumour
recurrence/progression was defined based on clinical, radiological
or histological diagnosis. The use of tissue samples was approved
by the Institutional Review Board (IRB) of Nagoya University
Graduate School of Medicine and by individual patients,
respectively.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections were cut at a
thickness of 4mm. For heat-induced epitope retrieval, deparaffi-
nized sections in 0.01 M citrate buffer (Target Retrieval Solution pH
6.1, Dako) were treated three times at 901C for 5min using a
microwave oven. Immunohistochemical staining was performed
using the avidin–biotin immunoperoxidase technique (Histofine
SAB-PO kit, Nichirei, Tokyo, Japan). Endogenous peroxidase
activity was blocked by incubation with 0.3% H2O2 in methanol for
15min, and nonspecific immunoglobulin binding was blocked by
incubation with 10% normal goat serum for 10min. Sections were
incubated at room temperature for 2h with primary antibody
(anti-AT1R at 1:100 dilution, anti-VEGF at 1:200, anti-CD34 at
1:40, anti-PCNA at 1:40). The sections were rinsed and incubated
for 30min with biotinylated second antibody. After washing, the
sections were incubated for 30min with horseradish peroxidase-
conjugated streptavidin, and finally treated with 3-amino-9-
ethylcarbazole (AEC) in 0.01% H2O2 for 10min. The slides were
counterstained with Meyer’s haematoxylin. As a negative control,
the primary antibody was replaced with normal rabbit IgG or
mouse IgG at an appropriate dilution. As positive immunohisto-
chemical controls, marked immunoreactivity of AT1R and VEGF in
placental trophoblastic tissues was confirmed as reported pre-
viously (Shiraishi et al, 1996; Ino et al, 2003). The immunostaining
intensity for AT1R and VEGF was scored semiquantitatively based
on the percent positivity of stained cells on a three-tiered scale as
follows:  , negative (no positive cells); þ, focally or weakly
positive (o50% positive cells); þþ, diffusely or strongly positive
(450% positive cells). In each case, at least three different areas
were evaluated and the mean of the results was considered to be
the expression intensity score. The staining procedure for each
antibody was repeated twice, and it was confirmed that there was
no difference in the staining intensity between the two experi-
ments. The scoring procedure was carried out twice by two
independent observers (each blinded to the other’s score) without
any knowledge of the clinical parameters or other prognostic
factors. The concordance rate was over 95% between the observers.
In the case of disagreement, the slides were reviewed simulta-
neously by these two observers, with another, different observer,
who were seated together at a multiheaded microscope in order to
resolve the difference of opinion.
Evaluation of tumour angiogenesis and proliferation
Tumour angiogenesis was assessed by counting the CD34-positive
capillaries and small venules, according to the method of Weidner
et al (1992). First, after scanning the immunostained section under
a light microscope at low magnification ( 40 and  100), the area
within the tumour having the highest number of distinct CD34-
staining microvessels (‘hot spots’) was selected. For the determi-
nation of intratumour MVD, all microvessels were counted within
the neovascular hot spot under a light microscope at  200
magnification ( 20 objective lens and  10 ocular lens). Two
investigators independently evaluated tumour vascularity without
any information about the clinicopathological features or expres-
sion scores for AT1R and VEGF. The average number of
microvessels of the three  200 fields that were strictly confined
to the hot spot area was recorded as the MVD, as described
previously (Ueda et al, 1999).
To assess proliferation, sections were immunostained with the
cellular proliferation marker PCNA as described previously
(Thomas et al, 1995; Fujimura et al, 2000). The PCNA labelling
index (PCNA LI) was defined as the number of tumour cells with
nuclear PCNA immunostaining divided by the total number of
tumour cells, and expressed as a percentage. A total of 1000 nuclei
in the selected area were counted under a light microscope at high
magnification ( 400 fields) and the mean percentages were
recorded as the PCNA LI.
Statistical analysis
Spearman’s rank correlation test was performed to analyse the
correlation between AT1R expression scores and various para-
meters. Fisher’s exact test or chi-square (w
2) test were also used to
analyse the distribution of AT1R-strongly positive cases, according
to clinicopathological, angiogenic and proliferative features.
Overall survival (OS) was calculated from the date of diagnosis
to the date of death, and progression-free survival (PFS) was
calculated from the date of diagnosis to the date of progression/
recurrence or date of last follow-up. Survival analyses were
performed according to the life tables method and according to
the Kaplan–Meier method. Comparison of the survival between
groups was performed with the log-rank test. Cox proportional-
hazard analysis was used for univariate and multivariate analysis
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(SAS Institute Inc., Cary, NC, USA) was used for all statistical
analyses and a P-value of o0.05 was considered significant.
RESULTS
Immunohistochemical expression of AT1R in ovarian
cancer tissues
As shown in Figure 1, the immunoreactivity of AT1R was detected
at variable levels, and was localized both on the membrane and in
the cytoplasm of tumour cells. There was no immunoreactivity of
AT1R in the tumour stroma. Of the 67 ovarian cancer specimens
examined in this study, AT1R was detected in 57 (85%) cases, of
which 37 (55%) were strongly positive. AT1R-negative tumours
were found in only 10 cases (15%).
Correlation of AT1R expression with clinicopathological,
angiogenic and proliferative parameters
The correlation of AT1R expression with clinicopathological,
angiogenic and proliferative parameters was analysed in 67 ovarian
cancer tissues. Type 1 angiotensin II receptors expression did not
significantly correlate with the histological subtype, FIGO stage or
histological grade (tumour differentiation) (Figure 2A–C). In
contrast, the AT1R expression positively correlated with the VEGF
staining scores (Figure 2D). Of the VEGF-strongly positive cases
(n¼24), 20 (83%) were AT1R strongly positive, while half (n¼9)
of the VEGF-negative cases (n¼18) were AT1R negative
(Figure 2D).
To determine the correlation between AT1R expression and
tumour angiogenesis, we assessed the intratumour MVD by
counting CD34-positive microvessels in the same series of ovarian
cancer tissues (n¼67). Microvessel density ranged broadly from
20 to 150 (mean¼75.2, median¼68). Thus, we defined cases with
MVD number of more than 70 as high MVD (n¼32), while cases
with MVD number of o70 were defined as low MVD (n¼35).
Interestingly, the AT1R expression score positively correlated with
MVD, and 28 (87.5%) of 32 high MVD cases were AT1R strongly
positive (Figure 2E). In this study, we confirmed that the MVD
number did not correlate with the histological subtype, FIGO stage
or histological grade, while VEGF expression scores positively
correlated with the MVD number (data not shown). Taken
together, our findings indicate that AT1R, as well as VEGF, are
associated with tumour angiogenesis of ovarian carcinoma.
Next, we assessed the correlation between AT1R expression and
tumour proliferation using immunohistochemical staining with
PCNA in the same series of ovarian cancer tissues. The PCNA LI
ranged from 16 to 80%, with a mean value of 50.16%, which is well
consistent with the results from a previous report (Thomas et al,
1995). We defined cases with a PCNA LI of more than 50 as high
PCNA LI (n¼37), while cases with a PCNA LI of o50 were defined
as low PCNA LI (n¼30). As shown in Figure 2F, the AT1R
expression score did not significantly correlate with PCNA LI.
The results from correlation analyses of AT1R overexpression
(strongly positive cases) with clinicopathological parameters,
VEGF expression, MVD and PCNA are summarized in Table 1.
These analyses demonstrated that AT1R overexpression was
significantly correlated with VEGF overexpression and high
MVD number, but not with the proliferation marker PCNA, nor
any of the clinicopathological factors examined in this study.
Correlation of AT1R expression with survival of ovarian
cancer patients
Follow-up data were available for 58 patients (nine patients were
lost to follow-up). The median follow-up was 60 months (range
1–121 months). During the follow-up period, the total number of
cases in which death and progression/recurrence were observed
was 19 (32.8%) and 25 (43.1%), respectively.
Figure 1 Representative immunohistochemical staining for AT1R in human ovarian cancer tissues. (A) Strongly positive; (B) weakly positive; (C) negative
in serous adenocarcinoma; (D) strongly positive in endometrioid adenocarcinoma; (E) strongly positive in clear cell adenocarcinoma; (F) negative control.
Original magnification,  100 in (A–F).
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Figure 2 Correlation of AT1R expression intensity with histological subtype (A), FIGO stage (B), histological grade (C), VEGF expression intensity (D),
MVD number (E), and PCNA LI (F) in ovarian cancer tissues. Significant correlation (Po0.05) was observed between AT1R expression and VEGF
expression (D), or between AT1R expression and MVD number (E), while there was no significant correlation between AT1R expression and other
clinicopathological factors or PCNA LI.
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overall survival (OS) and PFS curves were constructed using the
Kaplan–Meier method. The 5-year OS rates of patients who had
negative (n¼10), weakly positive (n¼18), and strongly positive
(n¼30) expression for AT1R were 100, 45.8 and 55.7%,
respectively (Figure 3A). The 5-year PFS rates of patients who
had negative, weakly positive, and strongly positive expression for
AT1R were 100, 27.5 and 41.9%, respectively (Figure 3B). Both OS
and PFS in patients with positive (weak and strong) expression for
AT1R were significantly lower than those in patients with negative
AT1R expression (P¼0.041 and 0.017, respectively, by log-rank
test). However, there was no significant difference in the
distributions of OS and PFS between the AT1R-weakly positive
and AT1R-strongly positive groups.
The correlation of VEGF expression, intratumour MVD, and
PCNA LI with prognosis was also analysed. The 5-year OS rates of
patients who had negative (n¼15), weakly positive (n¼22) and
strongly positive (n¼21) expression for VEGF were 92.9, 48.4 and
51.3%, respectively (Figure 3C). The 5-year PFS rates of patients
who had negative, weakly positive and strongly positive expression
for VEGF were 69.6, 47.6 and 24.2%, respectively (Figure 3D). Both
OS and PFS in patients with positive expression for VEGF were
significantly lower than those in patients with negative VEGF
expression (P¼0.046 and 0.036, respectively, by log-rank test),
although there was no significant difference in the distributions
of OS and PFS between the VEGF-weakly positive and strongly
positive groups. In contrast to AT1R and VEGF, there was no
significant difference in the distributions of OS and PFS according
to the MVD number (P¼0.203 and 0.467, respectively), or
according to the PCNA LI (P¼0.909 and 0.316, respectively), as
shown in Figure 3E–H. These results indicate that AT1R and
VEGF, but not the MVD number and PCNA LI, significantly
correlated with the impaired survival of ovarian cancer patients.
Multivariate analysis of prognostic variables in ovarian
cancer patients
Cox proportional-hazard analysis was performed to determine the
impact of various factors on survival. The results of univariate/
multivariate analyses of the variables, including AT1R, VEGF,
MVD and PCNA LI, with respect to OS and PFS are shown in
Tables 2 and 3, respectively. Because none of the patients with
negative AT1R expression (n¼10) died or recurred (no risk for OS
and PFS), the univariate analysis for AT1R expression (negative or
weakly/strongly positive) could not be performed, and it was not
entered into the multivariate analysis model. Among the other
six variables, the FIGO stage (P¼0.025) and VEGF expression
(P¼0.018) were statistically significant prognostic factors with
respect to OS on multivariate analysis (Table 2). Similarly, the
FIGO stage (P¼0.015) and VEGF expression (P¼0.008) were
found to be independent prognostic factors with respect to PFS on
multivariate analysis (Table 3).
DISCUSSION
In the present study, we demonstrated the expression of the type 1
angiotensin II receptor, AT1R, in human ovarian carcinoma
tissues, and its significant correlation with tumour angiogenesis
and patient survival. It has been reported that AT1R is expressed in
various human malignant tumour tissues, including breast cancer
(Inwang et al, 1997), skin cancer (Takeda and Kondo, 2001),
pancreatic cancer (Fujimoto et al, 2001), laryngeal carcinoma
(Marsigliante et al, 1996) and prostate cancer (Uemura et al, 2003).
Furthermore, we recently demonstrated that AT1R was expressed
in gynaecological malignancies, including cervical cancer (Kikkawa
et al, 2004), endometrial cancer (Watanabe et al, 2003),
choriocarcinoma (Ino et al, 2003), and ovarian cancer (Suganuma
et al, 2005). These findings suggest that AT1R exists in a wide
spectrum of human cancers, especially in gynaecological malig-
nancies, and that the angiotensin II-AT1R system may play
significant roles in the localized RAS within these tumour tissues.
Evidence for the involvement of AT1R in tumour progression, such
as growth, metastasis and angiogenesis, has accumulated in
various animal models (Rivera et al, 2001; Fujita et al, 2002;
Miyajima et al, 2002; Egami et al, 2003; Uemura et al, 2003; Arrieta
et al, 2005). Until now, however, there have been no reports
analysing the correlation of AT1R expression with clinical
parameters, especially with patient prognosis, using a large scale
of clinical samples of human cancers. Thus, the present study is the
first to investigate the correlation between AT1R and clinical
outcome in ovarian cancer patients.
Our immunohistochemical analysis showed that AT1R was
present in 85% of ovarian carcinomas examined, and it was
overexpressed in more than half (55%) of the cases. Furthermore,
AT1R expression was not dependent on the histological subtype,
grade or FIGO stage, although the rate of AT1R-negative cases was
relatively high in FIGO stage I (eight of 28 cases: 29%) as compared
to those in FIGO II–IV. Our prior studies showed that AT1R
expression was almost absent in benign ovarian cystadenoma, but
was dramatically upregulated with progression from borderline
malignancy to invasive ovarian carcinoma (Suganuma et al, 2005).
These results suggest the possible involvement of AT1R in the
specific cell behaviours that were common to the malignant
phenotypes, such as tumour cell invasion or aggressive neovascu-
larization, rather than in the degree of tumour differentiation or
histopathological subtypes.
Table 1 Correlation of AT1R overexpression with clinicopathologic
factors, and angiogenesis/proliferation markers in ovarian cancer
Patients AT1R overexpression
No. % No. % P-value
All cases 67 100.0 37 55.2
Histological type
Serous 22 32.8 13 59.1 0.777
a
Mucinous 12 17.9 7 58.3
Endometrioid 14 20.9 6 42.9
Clear cell 19 28.4 11 57.9
Histological grade
G1 24 35.8 14 58.3 0.576
a
G2 33 49.3 19 57.6
G3 10 14.9 4 40.0
FIGO stage
I 28 41.8 14 50.0 0.814
a
II 11 16.4 7 63.6
III 22 32.8 12 54.5
IV 6 9.0 4 66.7
VEGF expression
( ) 18 26.9 2 11.1 0.001
b
(+) 49 73.1 35 71.4
Microvessel density
704 35 52.2 9 25.7 0.001
b
70p 32 47.8 28 87.5
PCNA LI
504 30 44.8 14 46.7 0.205
b
50p 37 55.2 23 62.2
aw
2 test.
bFisher’s exact test.
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correlated with VEGF expression intensity in the ovarian
carcinomas examined in this study. Vascular endothelial growth
factor is known to be the main angiogenic factor in ovarian cancer
(Yamamoto et al, 1997; Fujimoto et al, 1998; Bamberger and
Perrett, 2002). It has been shown that angiotensin II upregulated
VEGF expression via AT1R (Chua et al, 1998; Pupilli et al, 1999;
Tamarat et al, 2002), and this angiotensin II-induced VEGF
upregulation was mediated by hypoxia-inducible factor-1, even in
non-hypoxic conditions (Richard et al, 2001). We have recently
reported that angiotensin II stimulated VEGF expression and
secretion in AT1R-positive ovarian cancer cells in vitro (Suganuma
et al, 2005). Furthermore, we found that ACE, an enzyme
producing angiotensin II in the RAS, was expressed in the tumour
stroma of ovarian cancer (data not shown). Thus, the positive
correlation between AT1R and VEGF observed in the present study
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Figure 3 Overall survival (OS) and progression-free survival (PFS) curves drawn using the Kaplan–Meier method according to the AT1R expression (A
and B), VEGF expression (C and D), MVD number (E and F), and PCNA LI (G and H). Significant differences in the OS and PFS according to the AT1R
expression (P¼0.041 and 0.017, respectively), and according to the VEGF expression (P¼0.046 and 0.036, respectively). No significant difference in the OS
and PFS according to the MVD (P¼0.203 and 0.467, respectively) and according to the PCNA LI (P¼0.909 and 0.316, respectively).
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suggests the existence of the angiotensin II-AT1R-VEGF system
controlling angiogenic signals in ovarian cancer.
In addition to VEGF, the intratumour MVD number also
positively correlated with AT1R expression intensity. Indeed, AT1R
was overexpressed in 87.5% of the cases with high MVD numbers
(more than 70). It is well known that MVD is a most reliable tool
for reflecting tumour angiogenesis (Weidner et al, 1992) and it
has been reported that VEGF expression directly correlated with
increased MVD in a variety of tumours (Toi et al, 1996; Maeda
et al, 1996). In the present study, we found the positive correlation
of MVD number not only with VEGF, but also with AT1R. These
findings support our hypothesis that AT1R is a key molecule in
tumour angiogenesis in ovarian cancer.
It has been reported that AT1R is involved in the proliferation of
various cancers in vitro and in vivo (Fujimoto et al, 2001; Rivera
et al, 2001; Muscella et al, 2002; Ino et al, 2003; Uemura et al,
2003). However, our immunohistochemical study showed that the
AT1R expression score did not significantly correlate with the
positivity of the cellular proliferation marker PCNA in ovarian
cancer tissues. Consistently, we previously reported that angio-
tensin II enhanced the invasive activity and VEGF secretion, but
not cell proliferation, in AT1R-positive ovarian cancer cell lines
in vitro (Suganuma et al, 2005). Taken together, it appears that
Table 2 Univariate and multivariate analyses of overall survival (OS) in ovarian cancer patients
Univariate analysis Multivariate analysis
Variables Categories Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
FIGO stage I/II 2.60 1.00–6.72 0.049 2.96 1.15–4.61 0.025
III/IV
Histological grade 1 or 2 0.19 0.02–1.56 0.122 0.22 0.03–1.71 0.147
3
AT1R expression ( )N D
a ND
a ND
a —— —
(+)/(++)
AT1R overexpression ( )/(+) 0.86 0.25–2.98 0.815 — — —
(++)
VEGF expression ( ) 5.75 0.71–46.52 0.101 12.18 1.54–96.37 0.018
(+)/(++)
MVD o70 0.27 0.09–0.77 0.145 0.30 0.11–0.84 0.122
X70
PCNA LI o50 1.13 0.44–2.88 0.805 — — —
X50
CI¼confidence interval.
aND¼not determined because no patients with negative AT1R expression died or recurred.
Table 3 Univariate and multivariate analyses of progression-free survival (PFS) in ovarian cancer patients
Univariate analysis Multivariate analysis
Variables Categories Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
FIGO stage I/II 2.29 1.02–5.14 0.044 2.70 1.21–6.04 0.015
III/IV
Histological grade 1 or 2 0.58 0.16–2.08 0.400 — — —
3
AT1R expression ( )N D
a ND
a ND
a —— —
(+)/(++)
AT1R overexpression ( )/(+) 0.85 0.26–2.75 0.789 — — —
(++)
VEGF expression ( ) 4.10 0.88–19.02 0.072 7.49 1.68–33.32 0.008
(+)/(++)
MVD o70 0.36 0.15–0.88 0.125 0.46 0.20–1.06 0.096
X70
PCNA LI o50 1.49 0.65–3.42 0.343 — — —
X50
CI¼confidence interval.
aND¼not determined because no patients with negative AT1R expression died or recurred.
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ovarian cancer, and that the angiotensin II-AT1R system plays
differential roles in cancer progression, which may be dependent
upon tumour type.
Our results from survival analyses demonstrated that both OS
and PFS were significantly poorer in AT1R-positive cases than
those in AT1R-negative cases. This provides the first evidence for
the positive correlation of AT1R expression with poor clinical
outcome in human malignancies. Surprisingly, we observed 100%
of the 5-year OS and PFS in AT1R-negative cases, although the case
number of these AT1R-non-expressing ovarian carcinomas was
small (n¼10) in this study. In addition, we showed that there was
no significant difference in the survival between AT1R strongly
positive and weakly positive within the AT1R-expressing cases.
These results might be unexpected because the immunohisto-
chemical analysis showed a clear correlation between overexpres-
sion (strongly positive) of AT1R with high VEGF expression and
high MVD numbers. One could speculate that the existence (either
high or low expression) of AT1R plays a crucial role in the
initiation of angiogenic signals in the primary lesions of ovarian
cancer, while other various molecules are complexly involved in
subsequent tumour progression, such as peritoneal dissemination
or distal metastasis. Similar to AT1R, both the OS and PFS in
VEGF-positive cases were significantly poorer than those in VEGF-
negative cases, which is consistent with the observation in previous
studies (Yamamoto et al, 1997; Shen et al, 2000). These findings
suggest that AT1R, as well as VEGF, may become a prognostic
marker for ovarian cancer patients; however, our multivariate
analyses showed that FIGO stage and VEGF, but not AT1R, were
independent prognostic factors for both OS and PFS. These results
may be due, at least in part, to the small number of patient
samples, because the AT1R-negative group consisted of only 10
patients, and there was no death or recurrence in this group.
Further studies, including multivariate analyses using a larger
sample size, are required to clarify whether AT1R can be an
independent prognostic factor or not.
In contrast to AT1R and VEGF, our study demonstrated that
there was no significant difference in the survival according to the
MVD number or PCNA LI. Previous studies showed that MVD was
not a useful prognostic factor in ovarian cancer (Obermair et al,
1999; Shen et al, 2000; Bamberger and Perrett, 2002). On the other
hand, Hollingsworth et al (1995) reported that MVD was
significantly correlated with poor prognosis of advanced stage
ovarian cancer, while conversely it was associated with better
prognosis (Ogawa et al, 2002). Correlation of the cellular
proliferation marker index, such as PCNA and Ki-67, with patient
survival is also controversial in ovarian cancer (Nakopoulou et al,
1993; Thomas et al, 1995; Itamochi et al, 2002). The reason for these
controversial findings remains unclear, but may be due at least in
part to the complicated mechanisms for tumour angiogenesis and
growth of ovarian cancer that are differentially regulated among the
histological subtypes (Bamberger and Perrett, 2002).
In summary, we demonstrated that AT1R expression was
associated with tumour angiogenesis of ovarian cancer and also
correlated with poor patient outcome. There has been accumulated
evidence that AT1R blockade therapy suppresses tumour growth,
metastasis and angiogenesis in experimental animal models
(Rivera et al, 2001; Fujita et al, 2002; Miyajima et al, 2002; Egami
et al, 2003; Uemura et al, 2003; Arrieta et al, 2005), and we also
demonstrated that an AT1R blocker suppressed the peritoneal
dissemination of ovarian cancer in a mouse model (Suganuma
et al, 2005). Combined with these findings, the present data suggest
that AT1R has clinical potential not only as a prognostic indicator,
but also as a novel molecular target in strategies for ovarian cancer
treatment.
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